Clinical Trial Update: Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of SGI-1776, a PIM kinase inhibitor, in refractory prostate cancer and relapsed/refractory non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Prostate Cancer

Drugs mentioned

• SGI-1776

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Prostate Cancer, Non-Hodgkins Lymphoma | Phase 1 | Status: TERMINATED